

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

Li-7

RRID:CVCL_3840

Type: Cell Line

Proper Citation

RRID:CVCL_3840

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3840

Proper Citation: RRID:CVCL_3840

Description: Cell line Li-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:85491](#), [PMID:2542205](#), [PMID:12029633](#), [PMID:15767549](#), [PMID:22460905](#), [PMID:23887712](#), [PMID:25877200](#), [PMID:30784169](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:37610679](#)

Comments: Population: Japanese., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Li-7

Synonyms: LI7, Li7, C-Li-7

Cross References: CLO:CLO_0050854, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:571, BioSample:SAMN03470992, BioSample:SAMN10987749, cancercellines:CVCL_3840, CCRID:1101HUM-PUMC000678, CCRID:3101HUMSCSP5062, CCRID:3101HUMTCHu183, Cell_Model_Passport:SIDM01472, CGH-DB:9074-4, CLS:305102, Cosmic:721062, Cosmic:2023862, Cosmic:2162529, Cosmic:2771607, DepMap:ACH-000471, FANTOM5_SSTAR:10484-107A7, GEO:GSM565882, GEO:GSM887266,

GEO:GSM888341, GEO:GSM2551577, IARC_TP53:30113, LiGeA:CCLE_219, LIMORE:Li7, PharmacDB:Li7_835_2019, PRIDE:PXD002486, Progenetix:CVCL_3840, RCB:RCB1941, TKG:TKG 0368, Wikidata:Q54902491

ID: CVCL_3840

Record Creation Time: 20220427T220726+0000

Record Last Update: 20260815T234500+0000

Ratings and Alerts

No rating or validation information has been found for Li-7.

No alerts have been found for Li-7.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo WW, et al. (2026) CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. International journal of biological sciences, 22(7), 3389.

Yasuda A, et al. (2026) Epigenetic regulation of the hepcidin gene expression in hepatoma cells. The FEBS journal.

Lu X, et al. (2025) Hypoxia- and Anoikis-Related lncRNA Signature Defines Molecular Subtypes and Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. Journal of hepatocellular carcinoma, 12, 2307.

Arora P, et al. (2025) Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. Journal of virology, 99(2), e0123024.

Yang Q, et al. (2024) Reduced representative methylome profiling of cell-free DNA for breast cancer detection. Clinical epigenetics, 16(1), 33.

Zhang J, et al. (2023) PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibition. Human cell, 36(5), 1755.

Xie W, et al. (2023) SYVN1 ubiquitinates FoxO1 to induce β -catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma. Cellular oncology (Dordrecht).

Zhang Q, et al. (2023) Hypoxia-Responsive lncRNA AC115619 Encodes a Micropeptide That Suppresses m6A Modifications and Hepatocellular Carcinoma Progression. *Cancer research*, 83(15), 2496.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.